Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor.

被引：0
|
作者：
Graff, Candace [1 ]
Schwartz, Annette [1 ]
Voss, Jeffrey [2 ]
Wishart, Neil [2 ]
Olson, Lisa [1 ]
George, Jonathon [2 ]
Hyland, Deborah [2 ]
Camp, Heidi [3 ]
机构：
[1] AbbVie Inc, AbbVie Biores Ctr, Worcester, MA USA
[2] AbbVie Pharmaceut, Worcester, MA USA
[3] Abbvie, Winnetka, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1499
引用
收藏
页码：S659 / S660
页数：2
相关论文
共 50 条
  • [21] Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
    Kondratyev, Maxim
    Rudnev, Vladimir R.
    Nikolsky, Kirill S.
    Stepanov, Alexander A.
    Petrovsky, Denis, V
    Kulikova, Liudmila, I
    Kopylov, Arthur T.
    Malsagova, Kristina A.
    Kaysheva, Anna L.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [22] A PHASE III RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF UPADACITINIB (ABT-494), A SELECTIVE JAK-1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
    Burmester, Gerd R.
    Kremer, Joel
    van den Bosch, Filip
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Pangan, Aileen L.
    Camp, Heidi S.
    RHEUMATOLOGY, 2018, 57
  • [23] A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
    Burmester, Gerd R.
    Kremer, Joel
    van Den Bosch, Filip
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Pangan, Aileen L.
    Camp, Heidi S.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [24] Discovery of the JAK1 selective kinase inhibitor AZD4205
    Kettle, Jason G.
    Su, Qibin
    Grimster, Neil
    Kawatkar, Sameer
    Throner, Scott
    Woessner, Richard
    Chen, Huawei
    Bebernitz, Geraldine
    Bell, Kristen
    Anderson, Erica
    Ruston, Linette
    Winter-Holt, Jon
    Lyne, Paul
    Vasbinder, Melissa
    Chuaqui, Claudio
    CANCER RESEARCH, 2017, 77
  • [25] Discovery of the JAK1 selective kinase inhibitor AZD4205
    Su, Qibin
    Kettle, Jason
    Grimster, Neil
    Vasbinder, Melissa
    Kawatkar, Sameer
    Throner, Scott
    Woessner, Rich
    Chen, Huawei
    Chuaqui, Claudio
    Bebernitz, Geraldine
    Bell, Kristen
    Anderson, Erica Anderson
    Ruston, Linette
    Winter-Holt, Jon
    Yang, Wenzhan
    Lyne, Paul
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [26] A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB (ABT-494), A SELECTIVE JAK-1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
    Burmester, G.
    Kremer, J.
    van den Bosch, F.
    Li, Y.
    Zhou, Y.
    Othman, A.
    Pangan, A.
    Camp, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 68 - 69
  • [27] PRECLINICAL CHARACTERIZATION OF CJ-15314, A HIGHLY SELECTIVE JAK1 INHIBITOR, FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Ki, S. Y.
    Shin, H.
    Lee, Y.
    Bak, H. R.
    Yu, H.
    Kim, S. C.
    Lee, J.
    Kim, D.
    Ko, D. H.
    Kim, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1343 - 1343
  • [28] Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
    Mesa, Ruben A.
    IDRUGS, 2010, 13 (06) : 394 - 403
  • [29] A PHASE-3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB (ABT-494), A SELECTIVE JAK-1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
    Burmester, Gerd R.
    Kremer, Joel M.
    van den Bosch, Filip
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Pangan, Aileen L.
    Camp, Heidi S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S88 - S88
  • [30] IN-115314, THE BEST SELECTIVE JAK1 INHIBITOR FOR THE TREATMENT OF ATOPIC DERMATITIS
    Choi, Jong-Ryoul
    Byeon, Yeji
    Yoon, Daseul
    Shin, Hyunwoo
    Lee, Juhyun
    Jung, Seunghee
    Ko, Donghyun
    Kim, Dongkyu
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 35 - 36
12345